TG Therapeutics, Inc. (TGTX)
Nasdaq · Healthcare · Biotechnology
$53.91−0.70%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $8.3B
- P/E (trailing)
- 19.6
- Forward P/E
- 19.9
- 52-week range
- $26.76 – $59.30
- 52-week change
- +47.69%
- EPS (trailing)
- $2.75
- Analyst rating
- 1.5 Strong buy
- Next earnings
- Nov 2, 2026
Fiscal year to Dec 2025
- Revenue
- $616M (+87.32%)
- Net income
- $447M
- Operating margin
- 20.0%
- Diluted EPS
- $2.77
- Free cash flow
- −$25.0M
From the company’s annual report on SEC EDGAR.
About TG Therapeutics, Inc.
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
Headquarters: Morrisville, United States · 399 employees · tgtherapeutics.com